<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01043666</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-090</org_study_id>
    <nct_id>NCT01043666</nct_id>
  </id_info>
  <brief_title>A Study of YM178 in Subjects With Symptoms of Overactive Bladder</brief_title>
  <official_title>Phase III Study of YM178: A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multi-center Study in Subjects With Symptoms of Overactive Bladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the efficacy and safety of YM178 in patients with symptoms of
      overactive bladder.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean number of micturitions per 24 hrs</measure>
    <time_frame>Within a 12-week treatment period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of urgency episodes per 24 hrs</measure>
    <time_frame>Within a 12-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of urinary incontinence episodes per 24 hrs</measure>
    <time_frame>Within a 12-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of urge incontinence episodes per 24 hrs</measure>
    <time_frame>Within a 12-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean volume voided per micturition</measure>
    <time_frame>Within a 12-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean number of nocturia episodes</measure>
    <time_frame>Within a 12-week treatment period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by vital signs, adverse events laboratory findings, 12-lead electrocardiogram and post-void residual volume</measure>
    <time_frame>During 12-week treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1126</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>YM178 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tolterodine ER group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM178</intervention_name>
    <description>oral</description>
    <arm_group_label>YM178 group</arm_group_label>
    <other_name>mirabegron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tolterodine ER</intervention_name>
    <description>oral</description>
    <arm_group_label>tolterodine ER group</arm_group_label>
    <other_name>Detrusitol SR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with symptoms of overactive bladder for at least 12 weeks before the study

          -  Subjects capable of walking to the lavatory without assistance and measuring the urine
             volume by him/herself

          -  Subject with an average frequency of micturition of 8 or more times per 24-hour period

          -  Subject with an average episode of urgency or urge incontinence of one or more times
             per 24-hours period

          -  Subject having provided written informed consent by him/herself

        Exclusion Criteria:

          -  Subject having stress urinary incontinence as a predominant symptom

          -  Subject with transient symptoms suspected for overactive bladder

          -  Subject complicated with urinary tract infection, urinary stones, and/or interstitial
             cystitis or with a historical condition of recurrent urinary tract infection

          -  Subject complicated with bladder tumor/prostatic tumor or with the historical
             condition

          -  Subject confirmed to have a post-void residual volume of &gt;=100ml or with a clinically
             significant lower urinary tract obstructive disease

          -  Subject with indwelling catheter or practicing intermittent self-catheterization

          -  Subject giving radiotherapy influencing urinary tract functions, or thermotherapy for
             benign prostatic hyperplasia

          -  Subject giving surgical therapy which may influence urinary tract functions within 24
             weeks before the study

          -  Subject with uncontrolled hypertension (indicated by sitting SBP &gt;=180mmHg or DPB &gt;=
             110mmHg)

          -  Subject with a pulse rate &gt;= 110bpm or &lt;50 bpm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hubei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jiangsu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liaoning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahmedabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurgaon</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chungcheong Namdo</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeollabuk</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeollanam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyonggi</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chia-Yi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hualien</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://www.astellasclinicalstudyresults.com/hcp/study.aspx?ID=168</url>
    <description>Link to results on Astellas Clinical Study Results website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2010</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Micturition</keyword>
  <keyword>YM178</keyword>
  <keyword>Urinary incontinence</keyword>
  <keyword>Frequency</keyword>
  <keyword>Overactive Bladder</keyword>
  <keyword>Urgency</keyword>
  <keyword>Urinary urge incontinence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolterodine Tartrate</mesh_term>
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

